Physician profile
Iselis Garcia
NPI 1659777480
$10,012.39
in general payments reported to CMS, 2019-2025
31 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $1,331 · 2023: $2,208 · 2024: $2,203 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,095 · Education: $92.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,095.21 |
| Education | $92.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,273.53 | 2021-2025 | |
| Janssen Biotech, INC. | $1,276.16 | 2021-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $861.67 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $816.46 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $540.50 | 2022-2025 | |
| Madrigal Pharmaceuticals | $513.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $396.93 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $263.66 | 2023-2025 | Omvoh |
| Celgene Corporation | $248.23 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $231.03 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $183.52 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $177.12 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $162.97 | 2021-2025 | |
| Vivus LLC | $154.46 | 2021-2024 | Qsymia |
| Pfizer INC. | $150.52 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $133.68 | 2023-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $72.83 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $71.48 | 2021-2023 | Givlaari |
| Redhill Biopharma INC. | $65.26 | 2021 | |
| Intercept Pharmaceuticals, INC. | $63.41 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $62.78 | 2025 | Iqirvo |
| Ardelyx, INC. | $53.30 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $52.58 | 2024-2025 | Vegzelma, Zymfentra |
| Alfasigma USA, INC. | $33.81 | 2021 | |
| Nestle Healthcare Nutrition INC. | $29.98 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.98 | 2022-2023 | Rebyota |
| Enterra Medical, INC. | $25.32 | 2025 | |
| Novo Nordisk INC | $22.03 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $19.39 | 2024 | Injectafer |
| Endo Pharmaceuticals INC. | $16.42 | 2022 | |
| Evoke Pharma, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iselis Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.